Introduction
============

Renal cell carcinoma (RCC) accounts for nearly 5% of adult malignancies with about 63,920 new cases and 13,860 deaths in the United States ([@ref-30]). RCC is histologically classified into several subtypes, including clear cell renal cell carcinoma (ccRCC), papillary cell carcinoma (pRCC), and chromophobe renal carcinoma (chRCC), among which ccRCC is the most common subtype and accounts for approximately 70--80% of all RCC ([@ref-39]). In addition to surgical treatment, current targeted therapies have slightly improved overall survival in patients with advanced disease. Histone lysine methyltransferase (HMT) and demethylases control the process of histone lysine methylation, which is a crucial part of epigenetics ([@ref-7]; [@ref-1]). To date, over 50 human HMTs have been revealed ([@ref-9]). In the structure, the HMTs are a group of various proteins, which are typically categorized by two functional enzyme families, the SET-domain-containing methyltransferase and DOT1L lysine methyltransferase ([@ref-1]; [@ref-9]) ([Table 1](#table-1){ref-type="table"}). Recent researches have shown that HMT dysregulation leads to uncontrollable histone methylation pathways and contributes to the pathogenesis of many human cancers, including RCC ([@ref-21]; [@ref-27]; [@ref-29]; [@ref-35]; [@ref-23]). Several studies indicated that the methyltransferase gene SETD2 was frequently mutated during epigenetic progress in RCC ([@ref-33]). It was also demonstrated that SETD2-mutated patients were characterized by loss of function of nucleosome structure, replisome occupancy, replication fork progression, and DNA repair by homologous replication ([@ref-14]). Also, EZH2, a histone 3 lysine 27 methyltransferase, proved to be associated with poor prognoses in ccRCC ([@ref-36], [@ref-37]). Increasing evidences showed that genetic alterations of several HMTs play crucial roles in oncogenesis ([@ref-29]; [@ref-27]; [@ref-32]). By far, there is no systematic analysis of genomic aberration of HMTs in RCC. Furthermore, the clinical relevance of genetic alterations in each HMT in RCC remains unclear. Our goal, therefore, is to demonstrate the genomic alteration of HMTs in RCC and assess their diagnostic and prognostic potential.
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###### Summary of identified human HMTs and their substrates.
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  Official symbol   Other aliases         Gene ID   Gene location   Histone substrates
  ----------------- --------------------- --------- --------------- --------------------
  SUV420H1          CGI85; KMT5B          51111     11q13.2         H4K20
  SUV420H2          KMT5C                 84787     19q13.42        H4K20
  ASH1L             ASH1; KMT2H; ASH1L1   55870     1q22            H3K4; H3K36
  SMYD1             KMT3D                 150572    2p11.2          H3K4
  SMYD3             KMT3E; ZMYND1         64754     1q44            H3K4
  SMYD2             KMT3C; ZMYND14        56950     1q32.3          H3K4; H3K36
  SMYD4             ZMYND21               114826    17p13.3         
  SMYD5             RRG1; RAI15           10322     2p13.2          
  NSD1              KMT3B                 64324     5q35.2          H3K36
  WHSC1             WHS; NSD2             7468      4p16.3          H3K36; H4K20
  WHSC1L1           NSD3; pp14328         54904     8p11.23         H3K4; H3K27
  DOT1L             DOT1; KMT4            84444     19p13.3         H3K79
  EZH1              KMT6B                 2145      17q21.2         H3K27
  EZH2              EZH1; KMT6            2146      7q36.1          H3K27
  SETD3             C14orf154             84193     14q32.2         
  SETD4             C21orf18; C21orf27    54093     21q22.12        
  SETD6                                   79918     16q21           
  SETD7             KMT7; SET7; SET9      80854     4q31.1          H3K4
  KMT2B             MLL2; MLL4            9757      19q13.12        H3K4
  KMT2C             HAIR; MLL3            58508     7q36.1          H3K4
  KMT2A             HRX; MLL; MLL1        4297      11q23.3         H3K4
  KMT2D             MLL2; MLL4            8085      12q13.12        H3K4
  SETD8             SET8; KMT5A; SETD7    387893    12q24.31        H4K20
  MECOM             EVI1; PRDM3           2122      3q26.2          H3K9me1
  PRDM16            MEL1; LVNC8; PFM13    63976     1p36.32         H3K9me1
  PRDM13            PFM10                 59336     6q16.2          
  PRDM8             PFM5                  56978     4q21.21         H3k9
  PRDM1             BLIMP1                639       6q21            
  PRDM2             RIZ; KMT8             7799      1p36.21         H3k9
  PRDM10            PFM7                  56980     11q24.3         
  PRDM12            PFM9                  59335     9q34.12         
  PRDM6                                   93166     5q23.2          
  PRDM14            PFM11                 63978     8q13.3          
  PRDM4             PFM1                  11108     12q23.3         
  PRDM15            PFM15; ZNF298         63977     21q22.3         
  PRDM5             BCS2; PFM2            11107     4q27            
  PRDM7             PFM4; ZNF910          11105     16q24.3         
  PRDM9             PFM6; MSBP3; PRMD9    56979     5p14.2          H3K4
  PRDM11            PFM8                  56981     11p11.2         
  EHMT1             GLP; KMT1D            79813     9q34.3          H3K9; H1.2K187
  EHMT2             G9A; NG36; KMT1C      10919     6p21.31         H3K9; H3K27
  SUV39H1           MG44; KMT1A           6839      Xp11.23         H3K9
  SUV39H2           KMT1B                 79723     10p13           H3K9
  SETD1A            Set1; KMT2F; Set1A    9739      16p11.2         H3K4
  SETD1B            KMT2G; Set1B          23067     12q24.31        H3K4
  SETDB1            ESET; KG1T; KMT1E     9869      1q21.3          H3K9
  SETDB2            CLLD8; CLLL8; KMT1F   83852     13q14.2         H3K9
  SETD2             SET2; HIF-1; HIP-1    29072     3p21.31         H3K36
  KMT2E             MLL5                  55904     7q22.3          H3K4
  SETD5                                   55209     3p25.3          
  SETMAR            Mar1; HsMar1          6419      3p26.1          H3K36

Materials and Methods
=====================

Samples with genomic and clinical data
--------------------------------------

The DNA copy number, gene expression, mutation, clinicopathological data and overall survival datasets of 882 RCC samples used in this research were obtained from The Cancer Genome Atlas (TCGA) at <https://genome-cancer.ucsc.edu>, including 528 ccRCC, 288 pRCC, and 66 chRCC samples. A total of 50 human HMTs were analyzed. In addition, 78 samples of Tokyo university downloaded from cBioportal were added to persuasively compare the tumor stage and overall survival between 62 SET-domain mutated patients and 16 non-SET-domain mutated patients. The copy number of HMTs is generated by the copy number algorithm genomic identification of significant targets in cancer algorithm analysis: "−2" represents a homozygous deletion, "−1" indicates a heterozygous deletion, "0" represents diploid, "1" indicates a low-level gain, and "2" signifies a high-level amplification. For mRNA expression data, the relative expression and gene expression profiles in the RCC samples were analyzed.

Statistical analysis
--------------------

Statistical analyses were performed using the R software ([@ref-41]), Graphpad Prism (version 7.01; GraphPad, La Jolla, CA, USA), and SPSS (version 18.0; SPSS, Chicago, IL, USA). The correlations between copy number alteration (CNA) and mutation status of 50 HMTs and 882 phenotypes of specimens were analyzed using Chi-square test. The CNA and mRNA expression of 46 HMTs from 882 sequenced RCC specimens were analyzed using Spearman, Kendall, and Pearson correlation tests. KMT2A, KMT2C, KMT2D, and KMT2E were excluded for lack of data. Heatmap of HMTs expression profiles in different subtypes of RCC was conducted by R statistical software. The Student's *t*-test was used in calculating differences in mRNA expression levels of each HMT between ccRCC and other subtypes. Kaplan--Meier survival curve was conducted to analysis the impact of CNA or gene expression of different HMTs on survival. Multivariate survival analysis was performed to investigate prognosis factors by Cox regression. The mRNA relative expression levels were analyzed by one-way analysis of variance. *P* \< 0.05 was considered statistically significant.

Gene set enrichment analysis
----------------------------

Gene set enrichment analysis (GSEA) was performed by GSEA software (Version 2.2.2), which was downloaded from the Broad Institute (<http://www.broad.mit.edu/gsea>). Enrichment map was generated for visualization of the GSEA results. False discovery rate value, normalized enrichment score, and adjusted *P*-value were calculated to identify the Hallmarks enriched in each phenotype.

Cell culture
------------

293T, HK-2 and ACHN cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum in an atmosphere at 37 °C with 5% CO~2~. 786-O and OSRC-2 cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum in an atmosphere at 37 °C with 5% CO~2~.

Quantitative real-time PCR
--------------------------

Total RNAs were extracted by MagZol (Invitrogen, Carlsbad, CA, USA) and cDNAs were synthetized by using SYBR Premix Ex TaqTM (TaKaRa, Kusatsu, Japan). Real-time PCR was performed by SYBR Green Realtime PCR Master Mix (TOYOBO, Osaka, Japan). Amplification conditions were as follows: 95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s for 40 cycles in a 20 μl reaction mix containing 2× SYBR Green. Primers for the reaction are provided in [Table S1](#supp-2){ref-type="supplementary-material"}.

Plasmids
--------

The shRNA plasmids for SETD2 and EZH2 knockdown were constructed from pSicoR (\#11579; Addgene, Watertown, MA, USA) with target sequences of shSETD2: TAGTACACCAAGACTCCAG, and shEZH2: CCAACACAAGTCATCCCATTA. All plasmids were verified by sequencing.

Cell viability, cell proliferation, cell migration, and invasion assays
-----------------------------------------------------------------------

Cell viability was assessed at 0, 24, 48, 72, and 96 h upon treatments by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) method (Promega, Madison, WI, USA, \#0000253755) according to the manufacturer's instructions. The MTS have six replications. Cell proliferation was estimated using the cell-light EdU Apollo 568 in vitro kit (Ribobio, GuangZhou, China. \#C10310-1) according to the manufacturer's instructions. Migration and invasion assays were performed using uncoated and Matrigel-coated Transwell inserts according to manufacturer's instructions. All experiments were performed in triplicate.

Results
=======

Genetic alterations of HMTs in renal cell carcinoma
---------------------------------------------------

Copy number alteration and somatic mutations are crucial mechanisms for oncogenesis or inactivating tumor suppressor genes in the occurrence and development of cancer ([@ref-2]). We hypothesized that genetic alterations of HMTs play significant roles in the development and progression of RCC ([@ref-42]). To systematically identify HMTs' potential of being biomarkers of diagnosis and prognosis of RCC, we first analyzed copy numbers and mutations of 882 RCC samples from the TCGA database via Cancer Browser ([@ref-40]). In Cancer Browser CNA datasets of RCC, as previously described, CNA was counted as "−2," "−1," "0," "1," and "2," and the average CNA rate of 50 HMTs was −0.0066. We found a different pattern of altered copy number and mutation of HMTs in RCC. Strikingly, as showed in [Table 2](#table-2){ref-type="table"}, seven HMTs (NSD1, PRDM6, MECOM, KMT2C, EZH2, PRDM14, and KMT2E) exhibited high-level amplification in more than 0.5% of RCC samples, and two of these seven HMTs (NSD1 and PRDM6) had a much higher amplification rate in over 10% of ccRCC samples. Three HMT genes, SETD2, SETD5, and SETMAR, showed homozygous deletion in more than 10% ccRCC samples. Intriguingly, NSD1 and PRDM6, the highest frequency of the top two HMTs with high-level amplification, were located in chromosome 5q; whereas SETD2, SETD5, and SETMAR, the highest frequency of the top three HMTs with homozygous deletion, were located in chromosome 3p. Additionally, KMT2C and SETD2 exhibited somatic mutations in more than 6% of ccRCC samples. Several studies revealed that SETD2 was frequently mutated in ccRCC and SETD2-mutated signal pathway played a vital role in the process of oncogenesis ([@ref-16]; [@ref-38]; [@ref-17]). Analogously, in our study SETD2 showed the highest mutation rate (11.51%) among 50 HMTs in ccRCC ([Table 2](#table-2){ref-type="table"}).
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###### Frequency of HMT copy number alterations and mutations (%).
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  Gene       Gene location   Amp     Gain    Diploid   Hetloss   Homdel   Mutation
  ---------- --------------- ------- ------- --------- --------- -------- ----------
  NSD1       5q35.2          16.67   46.21   35.98     1.14      0.00     2.82
  PRDM6      5q23.2          13.45   44.13   41.10     1.33      0.00     0.00
  MECOM      3q26.2          1.70    14.58   71.59     12.12     0.00     0.94
  KMT2C      7q36.1          1.14    32.20   65.53     1.14      0.00     6.10
  EZH2       7q36.1          0.95    32.20   65.72     1.14      0.00     0.47
  PRDM14     8q13.3          0.57    12.12   74.43     12.88     0.00     0.47
  KMT2E      7q22.3          0.57    32.58   66.67     0.19      0.00     1.41
  SETDB1     1q21.3          0.38    11.55   81.82     6.25      0.00     0.94
  ASH1L      1q22            0.38    11.74   81.44     6.44      0.00     0.94
  SETD1A     16p11.2         0.38    20.08   77.27     2.27      0.00     0.47
  KMT2A      11q23.3         0.38    5.87    89.02     4.73      0.00     1.88
  PRDM11     11p11.2         0.19    6.26    90.51     3.04      0.00     0.47
  SMYD3      1q44            0.19    10.80   81.06     7.95      0.00     0.00
  WHSC1L1    8p11.23         0.19    5.68    68.75     24.62     0.76     2.82
  SMYD2      1q32.3          0.19    10.98   81.25     7.58      0.00     0.47
  PRDM1      6q21            0.19    1.52    71.59     26.52     0.19     0.47
  SUV39H2    10p13           0.19    3.22    84.09     12.31     0.19     0.00
  PRDM9      5p14.2          0.19    32.01   66.86     0.95      0.00     0.47
  EZH1       17q21.2         0.19    5.68    88.45     5.68      0.00     0.47
  SUV39H1    Xp11.23         0.19    5.49    85.42     8.52      0.38     0.00
  PRDM7      16q24.3         0.19    18.56   77.08     4.17      0.00     0.47
  EHMT1      9q34.3          0.19    2.84    67.61     28.98     0.38     0.94
  PRDM10     11q24.3         0.19    5.49    88.83     4.92      0.57     0.00
  PRDM5      4q27            0.19    2.08    83.33     14.20     0.19     0.47
  DOT1L      19p13.3         0.19    8.71    87.50     3.22      0.38     0.94
  SETD7      4q31.1          0.19    2.65    82.95     14.02     0.19     0.00
  SMYD4      17p13.3         0.19    5.11    85.61     9.09      0.00     0.94
  SETDB2     13q14.2         0.19    3.98    80.49     15.15     0.19     0.00
  SUV420H1   11q13.2         0.00    6.25    90.15     3.60      0.00     1.41
  SUV420H2   11q13.2         0.00    10.80   88.07     0.95      0.19     0.47
  SETMAR     3p26.1          0.00    1.33    12.31     76.33     10.04    0.47
  SETD5      3p25.3          0.00    1.33    11.17     77.08     10.42    0.94
  EHMT2      6p21.31         0.00    1.89    79.17     18.94     0.00     1.41
  PRDM13     6q16.2          0.00    1.52    71.78     26.52     0.19     0.94
  PRDM15     21q22.3         0.00    9.66    79.55     10.42     0.38     0.47
  PRDM16     1p36.32         0.00    1.70    79.36     18.94     0.00     0.47
  SETD4      21q22.12        0.00    9.66    80.11     10.23     0.00     0.00
  SETD8      12q24.31        0.00    22.92   75.95     1.14      0.00     0.47
  PRDM12     9q34.12         0.00    2.46    68.37     28.98     0.19     0.00
  PRDM8      4q21.21         0.00    2.46    85.04     12.50     0.00     0.00
  SETD1B     12q24.31        0.00    22.92   75.95     1.14      0.00     0.00
  SETD3      14q32.2         0.00    2.84    53.60     43.18     0.38     1.41
  WHSC1      4p16.3          0.00    2.84    83.90     13.26     0.00     1.88
  KMT2D      12q13.12        0.00    22.73   76.33     0.95      0.00     1.41
  PRDM4      12q23.3         0.00    22.92   75.95     1.14      0.00     0.00
  SETD6      16q21           0.00    18.56   77.27     4.17      0.00     0.00
  SMYD5      2p13.2          0.00    14.39   82.95     2.65      0.00     0.00
  PRDM2      1p36.21         0.00    1.33    79.92     18.75     0.00     0.47
  SMYD1      2p11.2          0.00    14.39   83.14     2.46      0.00     0.00
  SETD2      3p21.31         0.00    1.14    10.80     77.27     10.80    11.51

**Notes:**

Amp = high-level amplification; Gain = low-level gain; Hetless = heterozygous deletion; Homdel = homozygous deletion.

Genes were ranked based on the frequency of high-level amplification.

Furthermore, HMTs showed different frequencies of CNA and mutation in different subtypes of RCC. Among the seven most frequently amplified HMTs, the frequencies of NSD1 and PRDM6 of high-level amplification were markedly higher in 528 ccRCC with more than 13.45% of tumor samples exhibiting amplificated when compared with that of 288 pRCC and 66 chRCC subtypes, which was less than 1.04% of tumor samples ([Fig. 1A](#fig-1){ref-type="fig"}). Also, SETD2 and SETD5 exhibited the highest frequency of homozygous deletion in ccRCC. However, neither of them exhibited homozygous deletion in pRCC and chRCC subtypes ([Fig. 1B](#fig-1){ref-type="fig"}). Additionally, in 213 ccRCC, 113 pRCC, and 65 chRCC, of the most commonly mutated HMTs, SETD2, and KMT2C were most frequently mutated in ccRCC and pRCC subtypes, whereas SETD2 was mutated in less than 1.54% of tumor samples and KMT2C did not exhibit mutation in chRCC ([Fig. 1C](#fig-1){ref-type="fig"}). The above data indicates that the subtype of ccRCC has a higher CNA and somatic mutation frequency in several HMTs, including amplification of NSD1 and PRDM6, homozygous deletion of SETD2, SETD5, and SETMAR, and mutation of KMT2C and SETD2.

![Frequencies of CNA of HMTs.\
(A) High-level amplification of seven HMTs in 528 ccRCC, 288 pRCC, and 66 chRCC samples, *P* \< 0.001 in NSD1, *P* \< 0.001 in RDM6, *P* \> 0.05 in other HMTs; (B) homozygous deletion of two HMTs in 528 ccRCC, 288 pRCC, and 66 chRCC samples, *P* \< 0.001 in SETD5, SETD2, and SETMAR; (C) mutation of two HMTs in 213 ccRCC, 113 pRCC, and 65 chRCC specimens, *P* \> 0.05 in KMT2C and *P* = 0.029 in SETD2. \**P* \< 0.05 \*\*\**P* \< 0.001.](peerj-07-6396-g001){#fig-1}

Gene expression and CNA profiling of HMTs in renal cell carcinoma
-----------------------------------------------------------------

The correlation between gene expression and copy number has been associated with the detection of human oncogenes. Therefore, we analyzed the correlation between copy number and gene expression level of 46 HMTs from 882 sequenced RCC samples which were divided into ccRCC and non-ccRCC (KIRP + KICH) groups. Four HMTs (KMT2A, KMT2C, KMT2D, and KMT2E) were excluded for lack of data. The rank correlation coefficients in the three statistical tests were similar for HMTs ([Table 3](#table-3){ref-type="table"}). As shown in [Table 3](#table-3){ref-type="table"}, HMTs were ranked based on the Spearman correlation coefficient, and the correlations between CNA and mRNA expression of 46 HMT genes were positive, and three of them (NSD1, WHSC1L1, SETDB1) showed a Spearman correlation coefficient greater than 0.5. (*P* \< 0.0001). WHSC1L1 exhibited the highest correlation coefficient by Pearson (*r* = 0.669), Spearman (*r* = 0.689) and Kendall (*r* = 0.596). Meanwhile, to investigate the degree of discretization of the data sets, the standard deviations of mRNA expression between the ccRCC and non-ccRCC subtypes was performed. As shown in the [Table 3](#table-3){ref-type="table"}, PRDM6 in ccRCC group had a higher degree of discretization than that of in non-ccRCC group.
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###### Associations between CNA and expression, and comparison of mRNA expression between ccRCC and non-ccRCC kidney cancer subtypes.
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  Gene       CNA/mRNA Correlation   ccRCC/non-ccRCC Comparison           
  ---------- ---------------------- ---------------------------- ------- -------
  WHSC1L1    0.689                  0.596                        0.669   −0.09
  SETDB1     0.580                  0.509                        0.597   −0.02
  NSD1       0.517                  0.449                        0.502   −0.08
  SMYD3      0.470                  0.419                        0.504   −0.34
  EZH2       0.462                  0.414                        0.459   −0.07
  SMYD2      0.433                  0.392                        0.427   −0.14
  SUV39H2    0.416                  0.376                        0.478   −0.09
  PRDM1      0.394                  0.357                        0.374   −0.10
  PRDM6      0.384                  0.343                        0.369   0.20
  ASH1L      0.380                  0.345                        0.389   −0.08
  SETD1A     0.273                  0.240                        0.234   0.02
  PRDM11     0.242                  0.215                        0.179   −0.07
  SMYD4      0.189                  0.177                        0.158   −0.07
  MECOM      0.176                  0.159                        0.156   −1.32
  PRDM8      0.162                  0.154                        0.164   −0.22
  PRDM13     0.161                  0.159                        0.103   −0.29
  SMYD1      0.159                  0.157                        0.185   0.06
  PRDM10     0.157                  0.149                        0.133   −0.10
  PRDM4      0.086                  0.089                        0.087   −0.26
  SUV420H1   0.087                  0.091                        0.085   −0.15
  SETD1B     0.071                  0.066                        0.058   −0.07
  EHMT1      0.070                  0.064                        0.079   0.01
  SETD8      0.068                  0.063                        0.058   −0.02
  SETD6      0.067                  0.062                        0.068   0.02
  SETMAR     0.063                  0.058                        0.043   −0.23
  EZH1       0.061                  0.057                        0.052   −0.02
  DOT1L      0.060                  0.056                        0.049   0.15
  SETD3      0.059                  0.055                        0.072   −0.10
  PRDM15     0.023                  0.019                        0.031   0.05
  WHSC1      0.022                  0.019                        0.010   −0.03
  SETD5      0.021                  0.018                        0.008   0.00
  PRDM7      0.020                  0.018                        0.015   −0.11
  PRDM14     0.018                  0.016                        0.023   −0.31
  SETDB2     0.016                  0.014                        0.021   −0.08
  PRDM5      0.011                  0.009                        0.003   −0.58
  PRDM12     0.010                  0.009                        0.001   −0.32
  PRDM9      0.009                  0.009                        0.002   −0.32
  PRDM16     0.008                  0.007                        0.048   −1.50
  PRDM2      0.008                  0.007                        0.020   −0.14
  SUV39H1    0.007                  0.006                        0.010   −0.03
  SETD4      0.003                  0.003                        0.017   −0.06
  SETD2      0.002                  0.002                        0.002   0.01
  SETD7      0.001                  0.001                        0.001   −0.07
  SMYD5      0.001                  0.000                        0.029   −0.06
  EHMT2      0.000                  0.000                        0.022   −0.14

**Notes:**

Genes were ranked based on the Spearman correlation coefficient. Significantly higher expression of HMTs in the ccRCC subtype is highlighted in dark gray, and significantly lower expression is highlighted in little gray. T statistics represents the T statistic, which is equivalent to the number of standard deviations of mRNA expression levels between the ccRCC and non-ccRCC subtypes. A positive value means that the ccRCC subtype has a higher value, and a negative value means that the ccRCC subtype has a lower value than the non-ccRCC subtypes samples.

Expression levels of the 46 HMTs was compared in the heatmap. Compared with non-ccRCC, mRNA levels of 10 HMTs (PRDM1, PRDM8, MECOM, PRDM16, SETD7, PRDM5, ASH1L, NSD1, SUV39H2, and SETDB1) were significantly higher (*P* \< 0.001) and 10 HMTs (PRDM12, SUV420H2, SETMAR, SETD1A, SETD2, SETD4, PRDM4, SETD8, DOT1L, and SETD1B) were significantly lower (*P* \< 0.001) in ccRCC ([Fig. 2](#fig-2){ref-type="fig"}; [Table S2](#supp-3){ref-type="supplementary-material"}).

![Heatmap of HMTs expression profiles in different types of renal cell carcinoma.\
The kidney cancer samples used in this analysis included 66 chRCC, 288 pRCC, 528 ccRCC kidney cancer samples. Significantly higher-expressed genes (*P* \< 0.001) in ccRCC tumors are shown at the top, indicated by a red box; and lower-expressed genes (*P* \< 0.001) in ccRCC tumors are indicated by a blue box.](peerj-07-6396-g002){#fig-2}

SETD2 and KMT2C mutations in clear cell renal cell carcinoma
------------------------------------------------------------

As described previously, we found that SETD2 and KMT2C are most frequently mutated HMTs in ccRCC, at rates of 11.51% and 6.10% ([Table 2](#table-2){ref-type="table"}). A systematic analysis of these mutation profiles was performed in ccRCC samples. Results showed that a total of 78 SETD2 mutations were found whereas 14 mutations were excluded because their data were untested. A total of 64 mutations were valid, including 18 nonsense mutations, 21 missense mutations, five frameshift insertions, eight frameshift deletions, six splices, and three other mutations. In addition, 24 KMT2C gene mutations were identified, including 10 missense mutations, five nonsense mutations, three frameshift deletions, two splice, and four other mutations ([Fig. 3A](#fig-3){ref-type="fig"}). A mutation map was performed to display the distribution of SETD2 and KMT2C mutations ([Fig. 3B](#fig-3){ref-type="fig"}). By systematic analysis of the mutation distribution, we found that SETD2 mutations were more likely to occur at SET domain area. Taking account of the crucial function of SET domain in SETD2, we predicted that mutations at the SET domain might result in the loss of methyltransferases features of SETD2 and poor prognosis of ccRCC patients. Therefore, we performed a Kaplan--Meier plots to investigate the clinical features between SETD2 SET domain mutation group and non-SET domain mutation group; results indicated that SETD2 SET domain mutation group was featured with advanced tumor stage and poor prognosis in ccRCC ([Fig. 4A](#fig-4){ref-type="fig"}).

![*KMT2C* and *SETD2* mutational spectrum in renal cell carcinoma.\
(A) Frequency of each mutation type for KMT2C and SETD2 from 213 renal cell carcinoma samples. The data were obtained from The Cancer Genome Atlas database via Cancer Browser. (B) The images show protein domains and the positions of specific mutations of KMT2C and SETD2. A red dot indicates a nonsense mutation, frameshift deletion, insertion, or splice; a green dot indicates a missense mutation; and a black dot indicates an inframe insertion or deletion.](peerj-07-6396-g003){#fig-3}

![SET domain mutation VS non-SET domain mutation.\
(A, B) Percentage of clinical stage of SETD2 domain mutation vs SETD2 non-SET domain mutation and Kaplan-Meier plots of overall survival associated with SETD2 domain mutation and SETD2 non-SET domain mutation. (C--F) SETD2 SET domain-mutated associated biological signaling pathways. Based on the TCGA dataset, GSEA showed genes associated with cell cycle, mitosis, transcription and DNA repair procedure were signifcantly enriched in SETD2 SET domain-mutated vs SETD2 non-SET domain-mutated tumors.](peerj-07-6396-g004){#fig-4}

Identification of SET-Domain associated biological process by GSEA
------------------------------------------------------------------

To identify SET-Domain associated biological process and function loss of SETD2 on a generalized level, GSEA was performed by using high throughput RNA-sequencing data of the TCGA cohort. The mutation state of SET domain was used as the phenotype label. Among all the predefined Hallmarks gene sets, DNA repair, E2F targets, G2M checkpoint, and mitotic spindle were found to be significantly associated with SET domain mutation in the TCGA cohort ([Fig. 4B](#fig-4){ref-type="fig"}).

HMTs CNA and expression and clear cell renal cell carcinoma patient survival
----------------------------------------------------------------------------

To explore the clinical association of genetic alterations of HMTs in RCC, we investigated the association between CNA, mRNA expression, and overall patient survival in 452 ccRCC samples, 76 ccRCC samples were excluded because their detailed survival data is not available in TCGA database. First of all, samples were divided into the following three groups for each HMT: amp/gain (high-level amplification/low-level gain), diploid, and deletion. For six HMTs (EZH2, NSD1, PRDM6, SETD2, SETD5, and SETMAR), copy number amp/gain and deletion were significantly related to poorer survival in RCC patients (*P* \< 0.05). Deletions of KMT2C and PRDM6 were related to shorter survival, however, only amp/gain of EZH2 and PRDM14 was more likely related to poorer survival. More importantly, deletion of NSD1 was significantly related to poorer survival; amp/gain of NSD1 was significantly related to longer survival, compared with diploid or deletion groups ([Fig. 5A](#fig-5){ref-type="fig"}; [Fig. S1](#supp-1){ref-type="supplementary-material"}).

![Clinical outcome with CNA or gene expression level of HMTs.\
(A--F) Kaplan-Meier plots of overall survival associated with copy number and mRNA expression levels of three HMTs (NSD1, PRDM6, and EZH2) in renal cell carcinoma. (G) Multivariate analysis (Cox model, n=428) of genetic alteration and gene expression of 11 HMTs (ASH1L, PRDM8, SETD1A, PRDM9, PRDM6, EHMT1, NSD1, WHSC1L1, PRDM7, SUV420H1 and DOT1L) and their HR values, respectively.](peerj-07-6396-g005){#fig-5}

To analyze the relationship between HMTs expression and overall survival of ccRCC patients, they were divided into low (*n* = 226) and high (*n* = 226) expression groups based on the mRNA expression of each HMT. High mRNA levels of EZH2, PRDM6, SETD5, and SETMAR were significantly associated with shorter survival in ccRCC patients, whereas only high NSD1 expression was correlated with longer survival in ccRCC (*P* \< 0.05) ([Fig. 5A](#fig-5){ref-type="fig"}; [Fig. S1](#supp-1){ref-type="supplementary-material"}).

A multivariate analysis by Cox model (*n* = 428) was performed to investigate the capability to predict poor prognosis of each HMT compared with standard prognostic markers, such as age at diagnosis, gender and tumor stage (stage I--stage IV). Results indicated that amp/gain of ASH1L had a hazard radio (HR), a ratio of death probabilities, of 1.533 compared with non-amp/gain of ASH1L in RCC patients. In addition, deletion of PRDM8 was significantly associated with shorter survival (HR = 1.516, *P* \< 0.05) in RCC patients. High mRNA levels of SETD1A (HR = 1.275) and PRDM9 (HR = 1.258) was significantly associated with shorter survival in RCC patients (*P* \< 0.05). However, higher expression of PRDM8 (HR = 0.739), EHMT1 (HR = 0.723), ASH1L (HR = 0.711), WHSC1L1 (HR = 0.674), and SUV420H1 (HR = 0.616) was negatively associated with shorter survival in RCC patients (*P* \< 0.05). Also, amp/gain of PRDM6 (HR = 0.703), PRDM9 (HR = 0.662), PRDM7 (HR = 0.640), SETD1A (HR = 0.638), NSD1 (HR = 0.598), and DOT1L (HR = 0.592) was negative correlated with shorter survival in RCC patients (*P* \< 0.05). ([Fig. 5B](#fig-5){ref-type="fig"}; [Table S3](#supp-4){ref-type="supplementary-material"}).

RT-PCR analysis of mRNA expression of important HMTs
----------------------------------------------------

Quantitative RT-PCR was performed to measure the expression level of eight important HMTs (NSD1, PRDM6, MECOM, EZH2, ASH1L, SETD1A, WHSC1L1, and SETD2). HK-2, a renal tubular epithelial cell line, was used as the control group. Relative expression of the eight HMTs in kidney cancer cell lines compared with HK-2 cell line was shown in [Fig. 6](#fig-6){ref-type="fig"}. It showed that mRNA levels of EZH2 were more than fourfold higher in kidney cancer cell lines. In contrast, mRNA levels of WHSC1L1, ASH1L, and NSD1 were more than onefold lower in kidney cancer cell lines. Notably, for SETD2 and MECOM, mRNA levels were more than threefold and sixfold lower in kidney cancer cell lines, respectively. However, mRNA level of PRDM6 did not show significant difference between RCC and control cell lines. These results indicated that there was a correlated change between CNAs and mRNA expression.

![mRNA expression levels of eight HMTs in three RCC cell lines (OSRC-2, 786-O, and ACHN) and renal tubular epithelial cell line (HK-2) measured by qRT-PCR.\
(A-H) mRNA relative expression level of 8 HMTs (NSD1, PRDM6, EZH2, WHSC1L1, SETD2, ASH1L, SETD1A, and MECOM) in OSRC-2, ACHN, 786-O, and HK-2 cell lines, the lowest gene expression level was set as "1" among the four cell lines. Relative expression levels are shown as fold changes compared with "1".](peerj-07-6396-g006){#fig-6}

Comprehensive identification of important HMTs in RCC
-----------------------------------------------------

According to previous data of these CNA, mutation, mRNA expression, and clinical outcome, [Table 4](#table-4){ref-type="table"} listed the integrative score of important HMTs. Every category counted as "+" when an HMT met the criteria. Especially, SETD2 and KMT2C counted as "++" in CNA/Mutations category because they met the two criteria. As shown in [Table 4](#table-4){ref-type="table"}, six HMTs (ASH1L, PRDM6, NSD1, EZH2, WHSC1L1, SETD2) had a score of more than 2, suggesting that these six HMTs may play important roles in RCC oncogenesis.

10.7717/peerj.6396/table-4

###### Integrative identification of critical HMTs in kidney cancer.

![](peerj-07-6396-g012)

  Gene       CNA/Mutations   CNA/mRNA correlation   Expression   mRNA/survial   CNA/survival   Score
  ---------- --------------- ---------------------- ------------ -------------- -------------- -------
  ASH1L      \+                                     \+           \+                            3
  PRDM8      \+                                                                                1
  SETD1A     \+                                     \+                                         2
  PRDM9      \+                                                                                1
  PRDM6      \+                                                  \+             \+             3
  EHMT1      \+                                                                                1
  NSD1       \+              \+                     \+           \+             \+             5
  WHSC1L1    \+              \+                     \+                                         3
  PRDM7      \+                                                                                1
  SUV420H1   \+                                                  \+                            2
  DOT1L      \+                                                                                1
  SETD2      ++                                     \+           \+                            4
  EZH2       \+                                     \+           \+                            3
  MECOM      \+                                     \+                                         2
  SETD5      \+                                                  \+                            2
  SETMAR     \+                                                  \+                            2
  KMT2C      ++                                                                                2
  KMT2E      \+                                                                                1

**Notes:**

CNA/Mutation, amplifcation, deletion or mutation; CNA/mRNA correlation, associations between CNA and gene expression; Expression, altered expression in RCC; mRNA/Survival, mRNA associated with patient survival; CNA/Survival, CNA associated with patient survival.

SETD2 inhibits cell proliferation in vitro, EZH2 promotes cell proliferation, migration and invasion in vitro
-------------------------------------------------------------------------------------------------------------

We performed MTS assays, Transwell migration/invasion assays and EdU assays in 786-O cell line to detect the function on cell proliferation and migration of SETD2 and EZH2. Assays showed a higher proliferative ability in 786-O cell line with SETD2 knockdown. However, the migration and invasion ability showed no significant differences with or without SETD2 knockdown. Meanwhile EZH2 knockdown reduced the ability of cell proliferation, migration, and invasion significantly. Results mentioned above ([Figs. 7](#fig-7){ref-type="fig"} and [8](#fig-8){ref-type="fig"}) were consistent with our preceding findings.

![SETD2 inhibits cell proliferation *in vitro*.\
(A) qPCR analysis of relative expression of SETD2 in sh-LacZ and sh---SETD2 cells. (B) MTS assays for 786-O cells without or with stably SETD2 knockdown. (C) and (D) Migration and invasion analyses of Transwell for 786-O cells without or with stably SETD2 knockdown. (E) and (F) EdU assays for 786-O cells without or with stably SETD2 knockdown. \**P* \< 0.05 \*\**P* \< 0.01 \*\*\**P* \< 0.001.](peerj-07-6396-g007){#fig-7}

![EZH2 promotes cell proliferation, migration and invasion *in vitro*.\
(A) qPCR analysis of relative expression of EZH2 in sh-LacZ and sh---SETD2 cells. (B) MTS assays for 786-O cells without or with stably EZH2 knockdown. (C) and (D) Migration and invasion analyses of Transwell for 786-O cells without or with stably EZH2 knockdown. (E) and (F) EdU assays for 786-O cells without or with stably EZH2 knockdown. \**P* \< 0.05 \*\**P* \< 0.01 \*\*\**P* \< 0.001.](peerj-07-6396-g008){#fig-8}

Discussion
==========

We performed a systematic analysis of 50 human HMTs in RCC samples of TCGA and clinical data. Our main findings were listed as follows: (1) A total of 12 HMTs were identified with the highest frequency of genetic alterations; (2) the highest frequency of the top two HMTs with high-level amplification were located in chromosome 5q; whereas the highest frequency of the top three HMTs with homozygous deletion were located in chromosome 3p; (3) correlation between gene expression and CNA was identified: all 46 HMTs showed a positive correlation and three HMTs (NSD1, WHSC1L1, SETDB1) had a Spearman correlation coefficient (*r*) greater than 0.5. WHSC1L1 exhibited the highest correlation; (4) Compared with non-ccRCC, mRNA levels of 10 HMTs (PRDM1, PRDM8, MECOM, PRDM16, SETD7, PRDM5, ASH1L, NSD1, SUV39H2, and SETDB1) were significantly higher and 10 HMTs (PRDM12, SUV420H2, SETMAR, SETD1A, SETD2, SETD4, PRDM4, SETD8, DOT1L, and SETD1B) were significantly lower in ccRCC; (5) the top two mutated HMTs, KMT2C, and SETD2, showed various of mutations at the SET domain in which many of SETD2 mutation were located, leading to loss of their methyltransferase functions; (6) we identified six HMTs (EZH2, NSD1, PRDM6, SETD2, SETD5, and SETMAR) which DNA copy number or mRNA expression level was significantly related to poorer survival in RCC patients; (7) mRNA levels of NSD1, WHSC1L1, ASH1L, SETD2, and MECOM were lower in renal cancer cells compared with renal tubular epithelial cell line whereas EZH2 and SETD1A exhibited the opposite; (8) SETD2 inhibits cell proliferation in vitro, EZH2 promotes cell proliferation, migration, and invasion in vitro.

Oncogenic alterations of HMTs, including amplification, homozygous deletion, and mutation, were associated with various human cancers, including RCC ([@ref-26]; [@ref-17]; [@ref-25]). EZH2 is overexpressed and mutated frequently in RCC and other types of tumors, contributing to tumorigenic potential of cancer ([@ref-5]). SETD2 is also a common tumor suppressor gene at chromosome 3p21, which is found to be mutated frequently in RCC ([@ref-25]; [@ref-38]; [@ref-11]).

Several studies indicated that aberrations of chromosome 3p deletion and gain of chromosome 5q were uncovered in ccRCC patients and presented their prognostic and diagnostic potential ([@ref-20]; [@ref-15]; [@ref-34]). Taking chromosome 3p as an illustration, ccRCC was characterized by a high frequency of allelic deletion or loss of heterozygosity on chromosome 3p, causing biallelic mutation or promoter hypermethylation of von Hippel-Lindau (VHL) gene. Similarly, our results indicated that SETD2, SETD5, and SETMAR were frequently deleted in ccRCC and they were located at 3p, implying their potential roles as tumor suppressors. Several researches explored their relationship between methylation of VHL promoter, SETD2 mutation and CNA of other genes located at 3p, including SETD5 and BAP1. As shown in [Table 3](#table-3){ref-type="table"}, WHSC1L1 showed the highest correlation between CNA and expression level and oncogenic potential in ccRCC, which was coincidently consistent with that of in breast cancer ([@ref-18]). Intriguingly, ccRCC patients were divided into two groups by WHSC1L1 mRNA expression level and the low expression group exhibited poorer prognosis, which was opposite from the role of WHSC1L1 in other cancers ([@ref-28]; [@ref-12]).

SETD2 was most mutated in ccRCC with highest frequency rate of 11.51%. SETD2 SET domain played a critical effect on affecting tumor stage of ccRCC patients. Clinical stage of patients with SETD2 mutations occurred in SET domain region were often higher than those of patients whose SETD2 mutations did not located in SET domain. Taking our results of the GO enrichment analysis into account, among all the predefined Hallmarks gene sets, DNA repair, E2F targets, G2M checkpoint, and mitotic spindle were found to be significantly associated with SET domain mutation, suggesting that SET domain mutation may be involved in ccRCC development and progression through the above cancer-associated biological processes ([@ref-24]; [@ref-8]; [@ref-22]). The above potential pathway involved in DNA repair, cell circle, dual chromatin, and cytoskeletal remodeling might constitute the reason for poor prognosis in patients with SETD2 mutations. Cell experiments revealed that SETD2 inhibits cell proliferation; however, the migration and invasion ability showed no significant differences. In numerous experimental settings, it has been established that SETD2 regulate cell growth in human cancers ([@ref-13]; [@ref-6]). Targeting SETD2 is believed to be a promising strategy for cancer therapy. However, an incomplete understanding of the molecular mechanisms that regulate SETD2 remains a barrier.

Furthermore, the other important HMTs including NSD1, PRDM6, EZH2, SETD5, WHSC1L1, and SETMAR were significantly associated with shorter survival in RCC patients. Except for EZH2, few of them were frequently identified and studied in kidney cancer. SETD5 was reported and identified as a new diagnostic marker in prostate cancer ([@ref-31]), which was consistent with our research. EZH2 is highly expressed in numerous cancers, including RCC ([@ref-37], [@ref-36]; [@ref-4]; [@ref-19]). Our findings showed that high EZH2 expression level was associated with tumor cell lines and poorer prognosis and in vitro experiments testified that EZH2 promoted cell proliferation, migration, and invasion in ccRCC. These results were consistent with preceding literature ([@ref-3]; [@ref-10]). Our findings suggest that EZH2 may contribute to renal cancer and raise the possibility that it may be essential for the maintenance of malignant phenotypes of renal cancers.

Conclusions
===========

In summary, our findings strongly evidenced that genetic alteration of HMTs may play an important role in generation and development of RCC, which lays a solid foundation for the mechanism for further research in the future.
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###### Kaplan-Meier plots of overall survival of SETMAR and SETD5 in renal cell carcinoma.

Kaplan-Meier plots of overall survival associated with copy number and mRNA expression levels of SETMAR and SETD5 in renal cell carcinoma.
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Click here for additional data file.
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###### Quantitative RT-PCR primers of eight important HMTs.
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###### Detailed information of expression levels of the 46 HMTs.

Expression of 46 HMTs and their detailed clustering analysis.

###### 

Click here for additional data file.
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###### Summary of multivariate analysis of overall survival for 10 HMT CNAs in renal cell carcinoma.

Risk factors, such as age (\>65), metastasis, lymph node (\>2) and tumor size (longest dimension\>1), were analyzed in the multivariate analysis.

###### 

Click here for additional data file.
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